Interferon-beta in the treatment of multiple sclerosis: Do clinical data support the existence of a ceiling effect?

Clinical Drug Investigation

Volumn 21, Issue 4, 2001, Pages 307-318

  Clanet, M ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MANUFACTURE; IMMUNOGENICITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0035064543     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121040-00009     Document Type: Review

References (34)

1. Interferons in multiple sclerosis
2. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
3. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
4. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
5. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
6. Evidence of interferon β-1a dose response in relapsing-remitting MS
7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II MRI analysis of a multicenter, randomized, double-blind, placebo-controlled trial
8. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing remitting MS
9. Interferon beta-1b in the treatment of multiple sclerosis. Final outcome of the randomized controlled trial
10. Placebo-controlled multicentre randomised trial of interferon β-1b in the treatment of secondary progressive multiple sclerosis
11. Effect of interferon-beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter randomized double-blind placebo-controlled trial
12. The effect of interferon beta 1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
13. The North American study of interferon beta-1b in secondary progressive multiple sclerosis
14. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: A review of the major clinical trials
15. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
16. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (Avonex): Rationale, design and baseline data
17. A randomised, double-blind, multicentric dose comparison study of interferon-beta-1a (Avonex) for the treatment of relapsing multiple sclerosis
18. PRISMS 4-year study results
19. Interferon Beta 1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study
20. Interferon beta-1a (Rebif®) in the treatment of secondary progressive multiple sclerosis. I. Clinical results [abtract no. 37]
21. Guidelines for use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
22. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
23. Development of a multiple sclerosis functional composite as a clinical trial outcome
24. Concurrent validity of the MS Functional Composite using MRI as a biological marker
25. Systemic recombinant human interferon beta treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
26. Ibuprofen treatment versus gradual introduction of interferon [β1b in patients with multiple sclerosis
27. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β)
28. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
29. Protein glycosylation: Implications for in vivo functions and therapeutic applications
30. Evaluation of interferon-beta immunogenicity in mice [abstract P01.075]
31. The effects of variable glycosylation on the functional activities of ribonuclease, plasminogen and tissue plasminogen activator
32. Concepts and principles of O-linked glycosylation
33. Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β- 1a and IFN-β- 1b treatment in multiple sclerosis
34. Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency and route of administration